ClinicalTrials.gg
Status unknownNCT03811548Updated Jul 16, 2020

Janagliflozin Treat T2DM Monotherapy

A Phase 3 interventional study of Janagliflozin 25mg and Janagliflozin 50mg in Diabetes Type 2, sponsored by Sihuan Pharmaceutical Holdings Group Ltd.. Status unknown at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2020-07-16.

Sponsored by Sihuan Pharmaceutical Holdings Group Ltd. · Phase 3, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Jul 2020), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
442
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 909 studies in Diabetes Mellitus, Type 2 with a site in China — 205 open to participants now, 228 under way, 46 of them phase 3. Diabetes Mellitus, Type 2 · China.

Planned enrollment
201st of 767
442 · median 199
Started
2019
with 51 others
Phase 3
207 of 909
38 open now
Registered
353rd of 909
by date

Among the 909 studies in Diabetes Mellitus, Type 2 with a site in China, this one is the 201st largest by planned enrollment of the 767 interventional ones that give a count, is one of 52 that started in 2019, is one of 207 in phase 3, and was the 353rd registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

205 of the 909 studies in Diabetes Mellitus, Type 2 with a site in China are open now. Recruiting first, the newest first:

200 more — sign in →

All 205 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 909 studies in Diabetes Mellitus, Type 2 with a site in China, or all of them as a file.
02

Study summary

The purpose of this study is to assess the effect of Janagliflozin relative to placebo on glycated hemoglobin (HbA1c) after 24 weeks of treatment, and to assess the efficacy after 52 weeks of treatment, overall safety and Population pharmacokinetics.

Read the detailed description

A multicentre, randomized, double-blind, parallel group, placebo-controlled study(24 weeks core period followed by 28 Weeks Extension period), to evaluate the efficacy and safety of Janagliflozin (25 mg and 50 mg) compared to placebo in patients diagnosed with T2DM who are not achieving an adequate response from diet and exercise to control their diabetes. Approximately 390 patients with inadequate glycemic control with diet and exercise will receive once-daily double-blind treatment with Janagliflozin 25 mg or 50 mg once daily for 52 weeks, or 24 weeks of double-blind treatment with placebo followed by 28 weeks of single-blind treatment with Janagliflozin 25 mg or 50 mg. During the treatment, if a patient's glycemic level remains high despite treatment with study drug and reinforcement with diet and exercise, the patient will receive treatment with metformin (rescue therapy) consistent with local prescribing information. Study drug will be taken orally once daily.

03

Conditions studied

  • Diabetes Type 2
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • All patients must have a diagnosis of T2DM (meet the diagnostic criteria for diabetes issued by the World Health Organization in 1999)
  • Patients must have a (HbA1c) level ≥7.5% and ≤11% at screening, and ≥7.0% and ≤10.5% at baseline.
  • Drug -naïve (never received anti-diabetic medication or did not receive anti-diabetic medication within 8 weeks before screening).
  • : 18.0\~35.0 kg/m2 (both inclusive)

Exclusion criteria

Exclusion Criteria:

  • History of type 1 diabetes mellitus (T1DM), diabetes caused by pancreatic injury, or secondary diabetes (e.g., diabetes caused by Cushing's syndrome or acromegaly)
  • More than 10% change in body weight within the 3 months before screening
  • Any laboratory test indicators meet the following standards:

    • fasting plasma glucose ≥ 15 mmol/L
    • , alanine aminotransferase levels > 3 times the (ULN); total > 1.5 times ULN
    • \< 100 g/L
    • \< 60 mL/min/1.73m2
    • fasting triglycerides > 5.64 mmol/L (500 mg/dL)
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
442 participants (estimated)

Study arms

  • Experimental
    Janagliflozin 25mg

    Each patient will receive 25 mg of Janagliflozin once daily for 52 weeks (24 weeks core period followed by 28 Weeks Extension period)

    Drug: Janagliflozin 25mg

  • Experimental
    Janagliflozin 50mg

    Each patient will receive 50 mg of Janagliflozin once daily for 52 weeks (24 weeks core period followed by 28 Weeks Extension period)

    Drug: Janagliflozin 50mg

  • Experimental
    Placebo/Janagliflozin

    In the core period, each patient will receive placebo once daily for 24 weeks and will then switch from placebo to 25 mg or 50 mg of Janagliflozin once daily until Week 52.

    Drug: Placebo/Janagliflozin

Interventions

  • Tablets, Oral, 25 mg, Tablets, Oral, 50 mg

    Also known as: Placebo 50mg

  • Tablets, Oral, 25 mg, Once daily, 52 weeks

    Also known as: Placebo 25mg

  • DrugPlacebo/Janagliflozin

    Tablets, Oral, 25 mg, Once daily, 52 weeks

06

What researchers measure

Primary outcomes

  1. Change in HbA1c From Baseline to Week 24

    To examine whether the mean change in HbA1c from baseline to week 24 with Janagliflozin is superiority (superiority margin of 0.5%) to placebo

    Time frame: Baseline and Week 24

Secondary outcomes

  1. Change in HbA1c From Baseline to Week 52

    To compare the mean change in HbA1c from baseline to week 52 between groups

    Time frame: Baseline and Week 52

  2. Percentage of Patients With HbA1c <7% at Week 24 (Core period) and week 52

    To compare the percentage of patients with HbA1c \<7% at week 24 (core period) and week 52 (extension period) between groups

    Time frame: Baseline, Week 24 and week 52

  3. Percentage of Patients With HbA1c <6.5% at Week 24 (Core period) and Week 52 (Extension period)

    To compare the percentage of patients with HbA1c \<6.5% at week 24 (core period) and Week 52 (extension period) between groups

    Time frame: Baseline, Week 24 and Week 52

  4. Change in Fasting Plasma Glucose (FPG) From Baseline to Week 24 (Core period) and Week 52 (Extension period)

    To compare the mean change in fasting plasma glucose (FPG) from Baseline to Week 24 (core period) and Week 52 (extension period) between groups

    Time frame: Baseline, Week 24 and Week 52

  5. Change in 2-hour Post-prandial Glucose From Baseline to Week 24 (Core period) and Week 52 (Extension period)

    To compare the mean change in 2-hour post-prandial glucose from Baseline to Week 24 (core period) and Week 52 (extension period) between groups

    Time frame: Baseline, Week 24 and Week 52

  6. Change in Blood Lipids (total cholesterol, triglycerides, high-density lipoprotein cholesterol, and low-density lipoprotein cholesterol) From Baseline to Week 24 (Core period) and Week 52 (Extension period)

    To compare the mean change in blood lipids (total cholesterol, triglycerides, high-density lipoprotein cholesterol, and low-density lipoprotein cholesterol) from Baseline to Week 24 (core period) and Week 52 (extension period) between groups

    Time frame: Baseline, Week 24 and Week 52

  7. Change in Blood Pressure (systolic blood pressure and diastolic blood pressure) From Baseline to Week 24 (Core period) and Week 52 (Extension period)

    To compare the mean change in blood pressure (systolic blood pressure and diastolic blood pressure) from Baseline to Week 24 (core period) and Week 52 (extension period) between groups

    Time frame: Baseline, Week 24 and Week 52

  8. Change in Body Weight From Baseline to Week 24 (Core period) and Week 52 (Extension period)

    To compare the mean change in body weight from Baseline to Week 24 (core period) and Week 52 (extension period) between groups

    Time frame: Baseline, Week 24 and Week 52

  9. Change in Fasting C-peptide From Baseline to Week 24 (Core period) and Week 52 (Extension period)

    To compare the mean change in fasting C-peptide from Baseline to Week 24 (core period) and Week 52 (extension period) between groups.

    Time frame: Baseline, Week 24 and Week 52

  10. Change in Insulin Sensitivity From Baseline to Week 24 (Core period) and Week 52 (Extension period)

    To compare the mean change in insulin sensitivity from Baseline to Week 24 (core period) and Week 52 (extension period) between groups

    Time frame: Baseline, Week 24 and Week 52

  11. Change in β-cell Function From Baseline to Week 24 (Core period) and Week 52 (Extension period)

    To compare the mean change in β-cell function from Baseline to Week 24 (core period) and Week 52 (extension period) between groups.

    Time frame: Baseline, Week 24 and Week 52

  12. Percentage of Patients Who Have Received Rescue Therapy at Week 24 (Core period) and Week 52 (Extension period)

    To compare the percentage of patients who have received rescue therapy by Week 24 (core period) and Week 52 (extension period) between groups

    Time frame: Week 24 and Week 52

Other outcomes

  1. Urinary albumin/creatinine ratio (UACR)

    To evaluate Urinary albumin/creatinine ratio in different group

    Time frame: From Baseline to Week 52

  2. Occurrence of adverse events

    To evaluate adverse events in different group

    Time frame: From Baseline to Week 52

  3. Occurrence of hypoglycaemic episodes

    To evaluate adverse events in different group

    Time frame: From Baseline to Week 52

  4. Population pharmacokinetics assessment

    By compare patients' Minimum Plasma Concentration (on week 2, 4, 8, 24)to eveluate Janagliflozin population pharmacokinetics characteristics

    Time frame: Baseline, Week 2, Week4, Week8, Week24

07

Study locations

1 of 1 sites recruiting
  • Linong Ji
    Beijing, Beijing, China
    Recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2019 to primary completion in Jun 2020, 13 months.

Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 13 months is below that.

Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 17, 2019
First posted
Jan 22, 2019
StartActual
May 23, 2019
Primary completionActual
Jun 24, 2020
CompletionEst.
Dec 31, 2020
Last update
Jul 16, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 16, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03811548
Responsible party
Sponsor
First posted
Jan 22, 2019
Start date
May 23, 2019
Primary completion
Jun 24, 2020
Completion
Dec 31, 2020 (estimated)
Last update
Jul 16, 2020

Study contacts

Leili Gao, Doctor
Contact
plum_jj@sina.com
00861088325578 ext. 00861088324516
Linong Ji, Doctor
Contact
jiln@bjmu.edu.cn
00861088325578 ext. 00861088324516

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jul 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Janagliflozin

Start the discussion